Researchers no difference between subcutaneous IV infliximab in IBD

SAN DIEGO — Subcutaneous infliximab maintained remission among patients with inflammatory bowel disease who switched from IV dosing, according to research presented at Digestive Disease Week 2022.“A subcutaneous (SC) formulation of infliximab (IFX) has recently been shown to be as effective as IV IFX in a randomized trial, but there are no real-world data to support elective switching,” Philip J. Smith, MD, a consultant luminal gastroenterologist and honorary senior lecturer at the University of Liverpool and Royal Liverpool Hospital in the United Kingdom, and colleaguesRead More

Related Articles